In a preclinical study, poly (β-L-malic acid)-based nanobioconjugate was developed in order to block the expression of laminin-411 in glioblastoma cancer, which is reported to correlate with high tumor grade and overexpression of CD133 and notch signaling pathway (putative markers of CSCs) [94]. Here, PROM1 is linked to neoplasm.